SCHEMBL6403447

SCHEMBL6403447

O=P(O)(O)Oc1cccc(O)c1C(O)CCCc1cccc(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.38
ANPEP P15144 1/20 0.37
ERAP2 Q6P179 1/20 0.37
ERAP1 Q9NZ08 1/20 0.37
F2 P00734 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
INPPL1 O15357 1/20 0.37
INPP5B P32019 1/20 0.37
INPP5A Q14642 1/20 0.37
POLB P06746 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
FDFT1 P37268 1/20 0.36
TYR P14679 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
OPRM1 P35372 2/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397757 0.94 ANPEP (0.40) ANPEPERAP2ERAP1F2INPPL1
SCHEMBL6403467 0.89 MGLL (0.37) MGLLANPEPERAP2ERAP1F2
SCHEMBL6397751 0.88 ACHE (0.39) INPPL1INPP5BINPP5AFDFT1CALM1
SCHEMBL6395844 0.88 INPPL1 (0.44) ANPEPERAP2ERAP1F2INPPL1
SCHEMBL6399804 0.83 ANPEP (0.39) ANPEPERAP2ERAP1F2INPPL1
SCHEMBL6396772 0.82 FDFT1 (0.39) MGLLANPEPERAP2ERAP1HDAC6
SCHEMBL6397574 0.82 CALM1 (0.39) MGLLANPEPERAP2ERAP1HDAC6
SCHEMBL6401939 0.81 INPPL1 (0.40) ANPEPERAP2ERAP1INPPL1INPP5B
SCHEMBL6396461 0.81 OPRK1 (0.40) MGLLANPEPERAP2ERAP1HDAC6
SCHEMBL6404356 0.80 MGLL (0.44) MGLLF2HDAC6INPPL1INPP5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885ANPEP 211/4885ERAP2 261/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MGLL 3439/4885ANPEP 191/4885ERAP2 248/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885ANPEP 211/4885ERAP2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.